Full text is available at the source.
Abstract
Nucleic acid therapies can trigger immune responses that may affect treatment efficacy and safety.
- Nucleic acid therapeutics, such as antisense oligonucleotides and small interfering RNAs, are emerging as important tools in precision medicine.
- These therapies can provoke unwanted immune reactions, which could negatively impact their effectiveness.
- A comprehensive immunogenicity risk assessment framework is proposed to tailor clinical testing strategies based on the immunogenic potential of different nucleic acid modalities.
- Recommendations include minimal monitoring for therapies with low immunogenic impact and extensive testing for those with safety concerns.
- The proposed strategies aim to facilitate the development of safe and effective nucleic acid-based therapies.
Simplified